RPRX

Royalty Pharma plc

Apr 09 • 09:47AM ET

47.90

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB REGN VRTX GILD INCY ALNY EXEL NBIX MDGL DKNG

| Held by: VXF VFLO VYM IWR SCHM IHE IWD CGDG COWG DGRO

Index	-	P/E	26.90	EPS (ttm)	1.78	Insider Own	7.35%	Shs Outstand	428.67M	Perf Week	-1.22%
Market Cap	27.63B	Forward P/E	9.05	EPS next Y	5.29	Insider Trans	-3.19%	Shs Float	396.92M	Perf Month	4.20%
Enterprise Value	39.20B	PEG	1.13	EPS next Q	1.12	Inst Own	85.67%	Short Float	2.92%	Perf Quarter	15.73%
Income	770.74M	P/S	11.62	EPS this Y	1.56%	Inst Trans	3.92%	Short Ratio	3.21	Perf Half Y	32.69%
Sales	2.38B	P/B	3.17	EPS next Y	7.93%	ROA	4.07%	Short Interest	11.58M	Perf YTD	23.96%
Book/sh	15.11	P/C	43.35	EPS next 5Y	8.00%	ROE	11.48%	52W High	49.06 -2.36%	Perf Year	48.44%
Cash/sh	1.11	P/FCF	10.65	EPS past 3/5Y	163.11% -7.26%	ROIC	5.12%	52W Low	30.04 59.45%	Perf 3Y	31.67%
Dividend Est.	1.00 (2.08%)	EV/EBITDA	25.10	Sales past 3/5Y	2.06% 2.30%	Gross Margin	-	Volatility	1.86% 1.95%	Perf 5Y	13.21%
Dividend TTM	0.89 (1.87%)	EV/Sales	16.48	EPS Y/Y TTM	-7.01%	Oper. Margin	65.56%	ATR (14)	0.96	Perf 10Y	-
Dividend Ex-Date	Feb 20, 2026	Quick Ratio	2.40	Sales Y/Y TTM	5.05%	Profit Margin	32.41%	RSI (14)	60.40	Recom	1.50
Dividend Gr. 3/5Y	5.01% 24.01%	Current Ratio	2.40	EPS Q/Q	6.83%	SMA20	2.65%	Beta	0.39	Target Price	52.43
Payout	49.40%	Debt/Eq	1.38	Sales Q/Q	4.71%	SMA50	5.18%	Rel Volume	0.38	Prev Close	47.90
Employees	100	LT Debt/Eq	1.33	Earnings	Feb 11 BMO	SMA200	21.34%	Avg Volume	3.60M	Price	47.90
IPO	Jun 16, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	14.02% 8.31%	Trades		Volume	124,041	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-26	Upgrade	UBS	Neutral → Buy	$49
Sep-30-25	Initiated	Goldman	Buy	$42
May-16-25	Initiated	Morgan Stanley	Overweight	$51
Jun-03-24	Downgrade	UBS	Buy → Neutral	$28
Jun-14-22	Resumed	UBS	Buy	$47
May-13-22	Initiated	Scotiabank	Sector Outperform	$53
Apr-27-22	Initiated	Goldman	Buy	$56
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight	$50
Apr-06-22	Resumed	Morgan Stanley	Overweight	$48
Oct-29-21	Upgrade	Citigroup	Neutral → Buy	$50
Jul-30-21	Initiated	Tigress Financial	Buy	$50
Nov-09-20	Upgrade	UBS	Neutral → Buy	$52 → $51
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	UBS	Neutral	$52
Jul-13-20	Initiated	SunTrust	Buy	$56
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight	$51
Jul-13-20	Initiated	JP Morgan	Neutral	$50
Jul-13-20	Initiated	Goldman	Neutral	$47
Jul-13-20	Initiated	Cowen	Outperform	$55
Jul-13-20	Initiated	Citigroup	Neutral	$50

Show Previous Ratings

Mar-30-26 07:15AM	Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases (GlobeNewswire)
Mar-23-26 07:15AM	Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence (GlobeNewswire)
Mar-17-26 04:01PM	Royalty Pharma Announces Expansion of Leadership Team (GlobeNewswire)
Mar-03-26 07:22PM	Royalty Pharma plc (RPRX) Earns $51 Target as 2026 Growth Outlook Exceeds Expectations (Insider Monkey)
05:24AM	Royalty Pharma (RPRX) Achieves Record Growth and Hits Investment Targets Ahead of Schedule (Insider Monkey)
06:50PM	Loading…
Mar-02-26 06:50PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
04:01PM	Zymeworks Inc (ZYME) Q4 2025 Earnings Call Highlights: Strategic Milestones and Financial Resilience (GuruFocus.com)
10:37AM	Zymeworks Q4 Earnings Call Highlights (MarketBeat)
08:30AM	Zymeworks Inc. Q4 2025 Earnings Call Summary (Moby)
07:00AM	Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform (GlobeNewswire)
06:10AM	Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing (GlobeNewswire)
Mar-01-26 04:27AM	TD Cowen Lifts PT on Royalty Pharma Plc (RPRX) to $50 from $45, Here's Why (Insider Monkey)
Feb-26-26 04:15PM	Royalty Pharma to Present at TD Cowen's 46th Annual Health Care Conference (GlobeNewswire)
02:11AM	Revolution Medicines Q4 Earnings Call Highlights (MarketBeat)
Feb-19-26 11:08PM	PTC Therapeutics Q4 Earnings Call Highlights (MarketBeat)
12:38AM	Loading…
Feb-18-26 12:38AM	5 Insightful Analyst Questions From Royalty Pharma's Q4 Earnings Call (StockStory)
Feb-12-26 09:07PM	Vertex Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
Feb-11-26 02:02PM	Royalty Pharma PLC (RPRX) Q4 2025 Earnings Call Highlights: Strong Growth and Strategic Capital ... (GuruFocus.com)
12:32PM	Royalty Pharma plc Q4 2025 Earnings Call Summary (Moby)
09:52AM	Royalty Pharma Q4 Earnings Call Highlights (MarketBeat)
09:30AM	Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q4 Earnings (Zacks)
07:32AM	Royalty Pharma: Q4 Earnings Snapshot (Associated Press Finance)
07:25AM	Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings (StockStory)
07:00AM	Royalty Pharma Reports Q4 and Full Year 2025 Results (GlobeNewswire)
Feb-10-26 09:15AM	Exploring Analyst Estimates for Royalty Pharma (RPRX) Q4 Earnings, Beyond Revenue and EPS (Zacks)
06:41AM	UBS and Citi Are Bullish on Royalty Pharma Plc (RPRX) - Here's Why (Insider Monkey)
Feb-09-26 10:06PM	What To Expect From Royalty Pharma's (RPRX) Q4 Earnings (StockStory)
Feb-05-26 11:38PM	3 Mid-Cap Stocks We Keep Off Our Radar (StockStory)
10:00AM	Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Feb-04-26 10:00AM	Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? (Zacks)
06:37AM	Loading…
Jan-24-26 06:37AM	Jim Cramer on Royalty Pharma: "It's a Terrific Company" (Insider Monkey)
Jan-23-26 05:42AM	Dianthus Therapeutics, Inc. (DNTH) Moves 9.9% Higher: Will This Strength Last? (Zacks)
Jan-22-26 08:53PM	Lightning Round: Coherent is a winner, says Jim Cramer (CNBC TV)
Jan-20-26 04:15PM	Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 (GlobeNewswire)
Jan-12-26 12:26PM	Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug (Benzinga)
10:08AM	TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug (Zacks)
08:55AM	Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings (Zacks)
07:15AM	Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-11-26 05:15PM	Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo (GlobeNewswire)
Jan-09-26 08:55AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
08:30AM	Royalty Pharma Announces Dividend Increase (GlobeNewswire)
01:52AM	Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal - Stock Soars Overnight (Benzinga)
Jan-07-26 10:37PM	Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX) (StockStory)
Dec-29-25 04:40PM	Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones (GlobeNewswire)
Dec-16-25 07:15AM	Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million (GlobeNewswire)
Dec-12-25 10:47AM	Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance (PR Newswire)
Dec-05-25 09:56AM	Denali Enters Into a $275M Funding Deal With Royalty Pharma (Zacks)
07:05AM	Denali makes $275m funding agreement with Royalty Pharma (Pharmaceutical Business Review)
Dec-04-25 07:10AM	Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement (GlobeNewswire)
Nov-26-25 08:15AM	Royalty Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-24-25 06:12AM	Vaximm and BCME link on oral cancer immunotherapy platform (Pharmaceutical Technology)
Nov-14-25 12:56PM	Eli Lilly Leads Three Stocks Near Buy Points (Investor's Business Daily)
Nov-12-25 11:03PM	Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
Nov-05-25 04:49PM	Analyst Report: Royalty Pharma plc (Morningstar Research) +6.82%
02:03PM	Royalty Pharma PLC (RPRX) Q3 2025 Earnings Call Highlights: Strong Portfolio Growth and ... (GuruFocus.com)
09:30AM	Royalty Pharma (RPRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:25AM	Royalty Pharma (RPRX) Beats Q3 Earnings and Revenue Estimates (Zacks)
07:23AM	Royalty Pharma: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Royalty Pharma Reports Third Quarter 2025 Results (GlobeNewswire)
Nov-04-25 07:15AM	Royalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences (GlobeNewswire)
Nov-03-25 10:34PM	Spotting Winners: Royalty Pharma (NASDAQ:RPRX) And Branded Pharmaceuticals Stocks In Q2 (StockStory)
10:15PM	What To Expect From Royalty Pharma's (RPRX) Q3 Earnings (StockStory)
Oct-31-25 12:41PM	How Royalty Pharma Prints Cash Without Biotech's Biggest Risks (MarketBeat)
Oct-29-25 10:00AM	Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? (Zacks)
12:02AM	2 Reasons to Avoid RPRX and 1 Stock to Buy Instead (StockStory)
Oct-28-25 01:34PM	1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data (MarketBeat)
12:24PM	What Do Analysts Think About Royalty Pharma Plc (RPRX)? (Insider Monkey)
Oct-17-25 09:10AM	Praxis Precision Medicines (PRAX) Surges 183.7%: Is This an Indication of Further Gains? (Zacks)
08:15AM	Royalty Pharma Declares Fourth Quarter 2025 Dividend (GlobeNewswire)
Oct-14-25 07:45AM	Kailera nets $600M more to advance Zepbound-like obesity drug (BioPharma Dive)
Oct-09-25 04:15PM	Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire)
Oct-08-25 12:10PM	Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Oct-06-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Oct-03-25 08:50AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
Sep-29-25 08:15AM	Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director (GlobeNewswire)
Sep-23-25 07:10PM	Royalty Pharma plc (RPRX) Completes $2B Senior Notes Offering, Strengthens Capital for Growth (Insider Monkey)
Sep-19-25 04:25PM	Royalty Pharma to Present at Bernstein's 2nd Annual Healthcare Forum (GlobeNewswire)
Sep-17-25 02:27PM	TD Cowen Maintains a Buy on Royalty Pharma (RPRX) (Insider Monkey)
12:43AM	1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore (StockStory)
Sep-16-25 09:28AM	Royalty Pharma plc (RPRX) Reports 20% Portfolio Growth, Posts $727M in Q2 Receipts (Insider Monkey)
Sep-11-25 11:13AM	Royalty Pharma plc (RPRX) Commits $300M to Zenas' Obexelimab Program (Insider Monkey)
07:00AM	Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation (GlobeNewswire)
Sep-10-25 07:30AM	Royalty Pharma Announces Release of Deloitte's Report on the Biopharma Royalty Market (GlobeNewswire)
Sep-04-25 04:15PM	Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire)
Sep-02-25 08:30PM	Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes (GlobeNewswire)
07:15AM	Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million (GlobeNewswire)
Aug-29-25 02:57PM	Royalty Pharma (RPRX) Strengthens Pipeline With New Oncology Royalty Purchase (Insider Monkey)
05:05AM	Royalty Pharma plc (RPRX) Boosts Growth with $885M Amgen Imdelltra Royalty Deal (Insider Monkey)
04:54AM	Royalty Pharma plc (RPRX) Strikes $2B Partnership with Revolution Medicines (Insider Monkey)
Aug-25-25 01:19PM	BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up (Benzinga)
08:29AM	Royalty Pharma buys BeOne stake in Amgen lung cancer drug sales (BioPharma Dive)
06:33AM	Royalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug (Reuters)
06:10AM	Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million (GlobeNewswire)
06:00AM	BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million (Business Wire)
Aug-13-25 04:15PM	Henry Fernandez Steps Down from Royalty Pharma's Board of Directors (GlobeNewswire)
01:35AM	5 Insightful Analyst Questions From Royalty Pharma's Q2 Earnings Call (StockStory)
Aug-12-25 09:10AM	Morgan Stanley Maintains a Buy Rating on Royalty Pharma Plc (RPRX) With a $55 PT (Insider Monkey)
03:18AM	RPRX Q2 Deep Dive: Margins Compress Despite Solid Royalty Growth and Strategic Investments (StockStory)
Aug-10-25 11:31PM	Reflecting On Branded Pharmaceuticals Stocks' Q2 Earnings: Royalty Pharma (NASDAQ:RPRX) (StockStory)
Aug-06-25 05:45PM	Analyst Report: Royalty Pharma plc (Morningstar Research)

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Coyne Terrance P.	EVP & CFO	Apr 01 '26	Sale	48.33	34,791	1,681,512	32,916	Apr 02 05:58 PM
Terrance Coyne	Officer	Apr 01 '26	Proposed Sale	48.49	34,791	1,687,016		Apr 01 04:55 PM
Coyne Terrance P.	EVP & CFO	Mar 23 '26	Sale	45.53	34,791	1,583,989	43,886	Mar 25 05:05 PM
Terrance Coyne	Officer	Mar 23 '26	Proposed Sale	45.61	34,791	1,586,818		Mar 23 04:43 PM
George Lloyd	Officer	Mar 19 '26	Proposed Sale	45.53	36,518	1,662,665		Mar 19 05:12 PM
George Lloyd	Officer	Mar 18 '26	Proposed Sale	45.79	100,462	4,600,155		Mar 18 06:02 PM
Coyne Terrance P.	EVP & CFO	Mar 02 '26	Sale	46.78	34,791	1,627,534	45,761	Mar 04 05:11 PM
George Lloyd	Officer	Mar 04 '26	Proposed Sale	47.43	136,980	6,496,961		Mar 04 04:52 PM
Terrance Coyne	Officer	Mar 02 '26	Proposed Sale	47.47	34,791	1,651,529		Mar 02 05:26 PM
Coyne Terrance P.	EVP & CFO	Feb 23 '26	Sale	45.32	34,791	1,576,606	47,636	Feb 25 04:08 PM
Terrance Coyne	Officer	Feb 23 '26	Proposed Sale	45.47	34,791	1,581,947		Feb 23 05:06 PM
Coyne Terrance P.	EVP & CFO	Feb 03 '26	Sale	42.84	114,954	4,924,997	23,972	Feb 04 05:07 PM
Coyne Terrance P.	EVP & CFO	Feb 02 '26	Sale	42.08	108,424	4,562,905	30,167	Feb 04 05:07 PM
Coyne Terrance P.	EVP & CFO	Feb 04 '26	Sale	43.29	20,163	872,913	22,885	Feb 04 05:07 PM
Terrance Coyne	Officer	Feb 03 '26	Proposed Sale	42.97	135,117	5,805,977		Feb 03 05:31 PM
Terrance Coyne	Officer	Feb 02 '26	Proposed Sale	42.36	108,424	4,592,841		Feb 02 05:28 PM
Urist Marshall	EVP, Research & Investments	Jan 30 '26	Sale	41.09	20,000	821,810	0	Feb 02 04:59 PM
Urist Marshall	EVP, Research & Investments	Jan 23 '26	Sale	40.26	20,000	805,110	20,000	Jan 26 04:10 PM
Coyne Terrance P.	EVP & CFO	Jan 20 '26	Sale	39.35	69,582	2,737,940	36,010	Jan 23 04:48 PM
Urist Marshall	EVP, Research & Investments	Jan 16 '26	Sale	39.52	20,000	790,346	40,000	Jan 20 05:00 PM
Terrance Coyne	Officer	Jan 20 '26	Proposed Sale	39.09	69,582	2,719,960		Jan 20 04:55 PM
Urist Marshall	EVP, Research & Investments	Jan 09 '26	Sale	40.78	20,000	815,634	60,000	Jan 13 05:37 PM
George Lloyd	Officer	Jan 07 '26	Proposed Sale	41.39	495,860	20,523,645		Jan 07 05:03 PM
Coyne Terrance P.	EVP & CFO	Jan 02 '26	Sale	38.42	69,582	2,673,041	39,760	Jan 06 04:18 PM
Urist Marshall	EVP, Research & Investments	Jan 02 '26	Sale	38.48	20,000	769,650	80,000	Jan 06 04:17 PM
Terrance Coyne	Officer	Jan 02 '26	Proposed Sale	38.86	69,582	2,703,957		Jan 02 06:22 PM
Urist Marshall	EVP, Research & Investments	Dec 26 '25	Sale	39.32	20,000	786,380	100,000	Dec 29 04:58 PM
Urist Marshall	EVP, Research & Investments	Dec 19 '25	Sale	38.38	20,000	767,582	120,000	Dec 22 04:09 PM
Lloyd George W.	EVP, Investments & CLO	Dec 17 '25	Sale	38.57	79,346	3,060,280	30,654	Dec 19 05:24 PM
Lloyd George W.	EVP, Investments & CLO	Dec 18 '25	Sale	38.50	30,654	1,180,053	0	Dec 19 05:24 PM
Urist Marshall	EVP, Research & Investments	Dec 16 '25	Sale	38.32	20,000	766,420	140,000	Dec 17 05:43 PM
Coyne Terrance P.	EVP & CFO	Dec 15 '25	Sale	38.36	69,582	2,669,172	43,510	Dec 17 05:39 PM
Sandy Lamm LLC	Officer	Dec 16 '25	Proposed Sale	38.36	160,000	6,137,600		Dec 16 09:41 PM
Terrance Coyne	Officer	Dec 15 '25	Proposed Sale	38.53	69,582	2,680,994		Dec 15 06:22 PM
Urist Marshall	EVP, Research & Investments	Dec 05 '25	Sale	39.15	23,334	913,591	160,000	Dec 09 05:00 PM
Urist Marshall	EVP, Research & Investments	Dec 05 '25	Sale	39.15	18,242	714,224	7,398	Dec 09 05:00 PM
Lloyd George W.	EVP, Investments & CLO	Dec 03 '25	Sale	39.77	110,000	4,375,008	110,000	Dec 05 05:01 PM
Coyne Terrance P.	EVP & CFO	Dec 01 '25	Sale	39.87	69,582	2,773,956	47,260	Dec 03 05:11 PM
Urist Marshall	EVP, Research & Investments	Dec 01 '25	Sale	39.93	23,333	931,633	183,334	Dec 03 05:10 PM
Urist Marshall	EVP, Research & Investments	Dec 01 '25	Sale	39.90	18,242	727,856	25,640	Dec 03 05:10 PM
Terrance Coyne	Officer	Dec 01 '25	Proposed Sale	39.90	69,582	2,776,322		Dec 01 05:53 PM
Urist Marshall	Officer	Dec 01 '25	Proposed Sale	39.90	36,484	1,455,712		Dec 01 05:10 PM
Sandy Lamm LLC	Officer	Dec 01 '25	Proposed Sale	19.93	46,667	930,232		Dec 01 04:48 PM
Coyne Terrance P.	EVP & CFO	Nov 24 '25	Sale	38.55	69,582	2,682,505	51,010	Nov 26 05:01 PM
Terrance Coyne	Officer	Nov 24 '25	Proposed Sale	39.75	69,582	2,765,884		Nov 24 05:24 PM
Lloyd George W.	EVP, Investments & CLO	Nov 19 '25	Sale	38.34	132,426	5,077,627	0	Nov 21 04:55 PM
Lloyd George W.	EVP, Investments & CLO	Nov 19 '25	Sale	38.34	3,000	115,029	0	Nov 21 04:55 PM
George Lloyd	Officer	Nov 19 '25	Proposed Sale	38.65	355,426	13,737,215		Nov 19 05:41 PM
Coyne Terrance P.	EVP & CFO	Nov 17 '25	Sale	39.30	69,594	2,735,329	54,760	Nov 19 04:53 PM
Terrance Coyne	Officer	Nov 17 '25	Proposed Sale	39.16	69,594	2,725,301		Nov 17 05:38 PM
Norden Gregory	Director	Aug 11 '25	Sale	36.23	33,500	1,213,749	194,848	Aug 11 04:35 PM
Norden Gregory	Director	Aug 11 '25	Proposed Sale	36.23	33,500	1,213,747		Aug 11 04:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RPRX

Royalty Pharma plc

Upgrade your Finviz experience